Alliancebernstein L.P. Has $182,000 Stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Alliancebernstein L.P. trimmed its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 9.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 246,121 shares of the biopharmaceutical company’s stock after selling 26,920 shares during the period. Alliancebernstein L.P. owned approximately 0.10% of Lexicon Pharmaceuticals worth $182,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in LXRX. Virtu Financial LLC acquired a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at approximately $66,000. Swiss National Bank boosted its stake in Lexicon Pharmaceuticals by 34.4% during the fourth quarter. Swiss National Bank now owns 426,600 shares of the biopharmaceutical company’s stock worth $315,000 after buying an additional 109,100 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 24,615 shares during the period. Geode Capital Management LLC raised its stake in shares of Lexicon Pharmaceuticals by 8.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock valued at $5,534,000 after buying an additional 273,436 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Lexicon Pharmaceuticals by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 863,255 shares of the biopharmaceutical company’s stock worth $638,000 after acquiring an additional 132,117 shares during the period. 74.70% of the stock is owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Stock Performance

Shares of NASDAQ:LXRX opened at $0.58 on Tuesday. The business has a fifty day moving average of $0.50 and a 200-day moving average of $0.86. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. Lexicon Pharmaceuticals, Inc. has a twelve month low of $0.28 and a twelve month high of $2.45. The firm has a market cap of $141.59 million, a PE ratio of -0.77 and a beta of 1.02.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The firm had revenue of $26.55 million during the quarter, compared to analysts’ expectations of $6.48 million. On average, equities research analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Leerink Partners reissued a “market perform” rating and issued a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. Piper Sandler cut their price objective on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Finally, Leerink Partnrs lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $3.67.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.